Navigation Links
Simcere Pharmaceutical Group to Announce Second Quarter 2011 Financial Results on Tuesday, August 9, 2011
Date:7/27/2011

NANJING, China, July 27, 2011 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2011 on Tuesday, August 9, 2011, before the market opens in the United States. Simcere's management will host an earnings conference call on the same day at 8 a.m. ET (Tuesday, August 9 at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:United States toll-free:+1.866.510.0708International:

+1.617.597.5377China Telecom:

10.800.130.0399 / 10.800.120.2655 / 10.800.152.1490China Netcom:

10.800.852.1490 / 10.800.712.2655China 400 (for mobile users)

400.881.1630 / 400.881.1629Hong Kong:

+852.3002.1672Please ask to be connected to Q2 2011 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 72942369.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:United States toll-free:+1.888.286.8010International:

+1.617.801.6888The passcode for replay participants is 99140552. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded and proprietary pharmaceuticals in China. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, cardiovascular disease, infectious diseases and pain. For more information about Simcere Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts: Email: ir@simcere.comIn Nanjing:Yehong Zhang

President

Simcere Pharmaceutical GroupTel: 86-25-8556-6666 ext 8811In the United States:Cindy Zheng

Brunswick Group

Tel: 1-212-333-3810In Beijing:Yue Yu

Brunswick Group

Tel: 86-10-5960-8600In Hong Kong:Joseph Lo Chi-Lun

Brunswick Group

Tel: 852-3512-5000  
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
2. Simcere Pharmaceutical Group Filed 2010 Annual Report on Form 20-F
3. Simcere Announces Recent Progress of Qiangkes Registration
4. Simcere Pharmaceutical Group to Announce First Quarter 2011 Financial Results on Tuesday, May 10, 2011
5. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2010 Results
6. Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2010 Unaudited Financial Results on Tuesday, March 8, 2011
7. Simcere Pharmaceutical Group Appoints Industry Veteran Mr. Hong Zhao as Executive Vice President of Sales and Marketing
8. Simcere Pharmaceutical Group Announces Resignation of CFO Frank Zhao
9. Simcere Pharmaceutical Group to Announce Third Quarter 2010 Financial Results on Thursday, November 11, 2010
10. Simcere Pharmaceutical Group to Announce Second Quarter 2010 Financial Results on Thursday, August 12, 2010
11. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... --  PDI , a leader in infection prevention products ... session focused on the role of chlorhexidine gluconate (CHG) ... 2017 Annual Scientific Meeting of the Association for Vascular ... Phoenix Convention Center in ... also feature PDI,s Prevantics® Device Swab as ...
(Date:9/5/2017)... , Sept. 5, 2017 Sapheneia and ... DoseCheck solution. Scannerside DoseCheck is a third-party Vendor neutral ... CT scanners and allows compliance with current MITA standards. ... proprietary XR 29 DoseCheck solution is specifically designed to ... alerts of potential radiation doses over a predefined threshold. ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months after ... is pleased to announce the appointment of three new ... Wynne , Dominic Jones-Phillips and James ... Tammy Wynne ... of market access writers. She has over ten years, ...
Breaking Medicine Technology:
(Date:9/22/2017)... , ... September 22, 2017 , ... Fenwick Agency of ... the communities they serve as part of the nationally recognized ‘Agents of Change’ movement. ... with nonprofit organizations and community leaders to seek out those who most need help. ...
(Date:9/22/2017)... ... ... Happy Living’s mission - to improve the health and wellbeing of the world, ... worlds of theatre and wines. , After watching Scott Barry perform on stage ... into a book. The Greener The Grass ( https://www.happyliving.com/books/the-greener-the-grass ) was published on March ...
(Date:9/22/2017)... ... September 22, 2017 , ... "Success Files," a short- and ... Alzheimer’s is a disease estimated to affect the lives of more than 5 ... Alzheimer’s Association, a leading voice in the fight for cure and research into ...
(Date:9/22/2017)... ... 22, 2017 , ... Egg freezing and embryo freezing are ... a slight statistical advantage for live births, frozen eggs offer many advantages, depending ... undergoing medical treatment or who are concerned about the decline of their fertility ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... SABRE is ... run from September 11 to the end of November. , The Chicago, Illinois, based ... their community and teach them about the ease of taking their personal safety into ...
Breaking Medicine News(10 mins):